Subscribe To
Vyant bio ends 2021 with $20.6m in cash as it sharpens focus on novel drug discovery
Vyant Bio (NASDAQ:VYNT) Inc ended its 2021 financial year with a beefed-up cash balance of $20.6 million to help the biotechnology company pursue its ...
March 30, 2022, 12:06 pm
Synaptogenix to present at hanson wade 10th annual neurodegenerative drug development summit
NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company...
March 29, 2022, 9:15 am
Vyant bio announces investor conference call and webcast for the year-end 2021
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology ...
March 28, 2022, 4:30 pm
Synaptogenix to present at sachs 5th annual neuroscience innovation forum
NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company ...
March 22, 2022, 9:15 am
Synaptogenix to present research highlighting potential broad applicability for lead compound bryostatin at the international conference on alzheimer's and parkinson's diseases (ad/pd 2022)
NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutic...
March 15, 2022, 9:15 am
Brainstorm to announce fourth quarter and fiscal year 2021 financial results and provide a corporate update
NEW YORK, March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for ...
March 14, 2022, 6:00 am
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Ac immune to present at the svb leerink 11th annual global healthcare conference
LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision ...
February 2, 2022, 8:58 am
Ac immune to present at the svb leerink 11th annual global healthcare conference
LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision ...
February 2, 2022, 8:58 am
Ac immune to present at the svb leerink 11th annual global healthcare conference
LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision ...
February 2, 2022, 8:58 am
Sio gene therapies to present at the 18th annual worldsymposium™ 2022
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing ...
February 2, 2022, 7:00 am
Sio gene therapies to present at the 18th annual worldsymposium™ 2022
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing ...
February 2, 2022, 7:00 am
Sio gene therapies to present at the 18th annual worldsymposium™ 2022
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing ...
February 2, 2022, 7:00 am
Brainstorm cell therapeutics to present at the 12th annual california als research summit
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for
January 27, 2022, 7:00 am
Brainstorm cell therapeutics to present at the 12th annual california als research summit
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for
January 27, 2022, 7:00 am
Brainstorm cell therapeutics to present at the 12th annual california als research summit
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for
January 27, 2022, 7:00 am
Neurosense: advancing generic combos in neurodegenerative diseases
NeuroSense Therapeutics is advancing a breakthrough treatment for ALS and other neurodegenerative disea...
December 21, 2021, 9:48 pm
Neurosense: advancing generic combos in neurodegenerative diseases
NeuroSense Therapeutics is advancing a breakthrough treatment for ALS and other neurodegenerative disea...
December 21, 2021, 9:48 pm